Our aim was the integration of PSMA-based imaging in the personalized process of radiation therapy of prostate cancer patients and the evaluation of its impact on target volume definition, especially for stereotactic body radiotherapy (SBRT) in the case of postoperative local recurrence and oligometastatic prostate tumors. The gene discussed is FOLH1; the disease is prostate carcinoma.